Related Experiment Video
Updated: Aug 25, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
p53 pathway in renal cell carcinoma is repressed by a dominant mechanism
Katerina V Gurova1, Jason E Hill, Olga V Razorenova
1Department of Molecular Biology, Lerner Research Institute, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA. gurovak@ccf.org
Abstract:
Renal cell carcinoma (RCC) rarely acquires mutations in p53 tumor suppressor gene, suggesting that p53 signaling in this tumor type might be repressed by some other mechanism. In fact, all four RCC-derived cell lines we tested maintained wild-type p53 but were not capable of transactivating p53-responsive reporters and endogenous p53-responsive genes. p53 protein in RCC showed normal response to genotoxic stress, including accumulation, nuclear translocation, and activation of specific DNA binding. Functional and expression analysis of Mdm2, MdmX, and Arf showed lack of involvement of these p53 regulators in the observed defect of p53 function in RCC. However, activation of p53-mediated transactivation could be achieved by extremely high levels of p53 attained by lentivirus vector-driven transduction, suggesting the involvement of a dominant inhibitor in repression of p53-dependent transactivation in RCC. Consistently, p53 inactivation prevailed in the hybrids of RCC cells with the cells possessing fully functional p53. Remarkably, cells of normal kidney epithelium also caused partial p53 repression in cell fusion experiments, suggesting that RCC-specific p53 repression may be based on an unknown dominant mechanism also acting in normal kidney tissue.
Insights
Renal cell carcinoma (RCC) rarely mutates the p53 gene. Instead, a dominant inhibitor likely represses p53 function, a mechanism also observed in normal kidney cells.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Renal cell carcinoma (RCC) infrequently harbors p53 mutations.
- This suggests alternative mechanisms may suppress p53 signaling in RCC.
Purpose of the Study:
- To investigate the mechanism of p53 repression in renal cell carcinoma.
- To determine if known p53 regulators are involved in this repression.
Main Methods:
- Analysis of p53-responsive gene transactivation in RCC cell lines.
- Assessment of p53 protein response to genotoxic stress.
- Functional and expression analysis of Mdm2, MdmX, and Arf.
- Cell fusion experiments with RCC and normal kidney cells.
Main Results:
- RCC cell lines with wild-type p53 failed to transactivate p53-responsive genes.
- p53 protein accumulated and translocated normally upon genotoxic stress.
- Known p53 regulators (Mdm2, MdmX, Arf) were not implicated in the p53 defect.
- p53 transactivation was restored only at supra-physiological p53 levels, suggesting a dominant inhibitor.
- Cell fusion experiments indicated a dominant inhibitory mechanism also present in normal kidney epithelium.
Conclusions:
- p53 signaling is repressed in renal cell carcinoma not by mutation, but by a dominant inhibitor.
- This dominant repression mechanism appears to be present in normal kidney epithelium as well.
- Further research is needed to identify the specific inhibitor and its role in both normal and cancerous kidney tissue.
Related Concept Videos
Abnormal Proliferation
Negative Regulator Molecules
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
